Clinical Case Study: Targeting BCMA With ADCs in MM

Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.
Paul G. Richardson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 507 KB
Released: November 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of use of asparaginase-based treatments in young and older adults with acute lymphoblastic leukemia

Wendy Stock, MD
Program Director
Emily Curran, MD Dan Douer, MD person default Scott Howard, MD, MSc person default Stephen P. Hunger, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 24, 2022 Expired: January 23, 2023

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings